Blog – Page 597

Tezspire (Tezepelumab), Monoclonal Antibody for the Treatment of Severe Asthma

By ApoThera April 5, 2022Blog

Drug Info: ApoThera Drug Disease Clinical Support App Severe Asthma - 210 mg SC every 4 weeks - Add-on maintenance treatment of severe asthma Missed Dose - Administer dose as…

Opdualag (Nivolumab-Relatlimab), for the Treatment of Melanoma

By ApoThera April 5, 2022Blog

Drug Info: ApoThera Drug Disease Clinical Support App Melanoma Unresectable or Metastatic - 480mg/160mg IV every 4 weeks - Continue until disease progression or unacceptable toxicity occurs Infusion-related Reactions Grade…

COVID-19 Viral Load, Onset of Symptoms Timeline & Antibody Response

By ApoThera April 5, 2022Blog

Rinvoq (upadacitinib) New Indications: Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

By ApoThera April 4, 2022Blog

Drug Info: ApoThera Drug Disease Clinical Support App Rinvoq (upadacitinib) receives FDA approval for the treatment of adults with moderately to severely active Ulcerative Colitis (UC) Induction Dose - 45…